Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study

Xiaoxiao Wang | Xiaohe Li | Rui Jin | Jia Yang | Rui Huang | Lai Wei
Feng Liu | Huiying Rao

1Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing, China
2Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China

Correspondence
Feng Liu and Huiying Rao, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, 100044, China. Email: liu1116m@hotmail.com and rao.huiying@163.com

Abstract
Metabolic-associated fatty liver disease (MAFLD) is a series of liver diseases based on liver steatosis and metabolic disorders. Steatosis, as the core factor in MAFLD diagnosis, and fibrosis, as the major determinant of adverse outcomes of MAFLD, need to be assessed simply and accurately. In this study, we explored the significance of mid-upper arm circumference (MUAC) in evaluating liver steatosis and fibrosis in patients with MAFLD. We included 2397 cases with MAFLD from the 2017–2018 National Health and Nutrition Examination Surveys (NHANES) database. Liver steatosis and fibrosis were measured by vibration controlled transient elastography. Anthropometric parameters and demographic and serological data were obtained from the NHANES database. The association between MUAC and liver steatosis and fibrosis were evaluated by a multivariable linear regression model, a weighted generalized additive model, and smooth curve fitting using R. MUAC was positively associated with liver steatosis in every multivariate linear regression model (model 1: \( \beta = 3.3513 \), 95% confidence interval [CI], 2.7722–3.9304; model 2: \( \beta = 3.8492 \), 95% CI, 3.2441–4.4542; model 3: \( \beta = 2.4987 \), 95% CI, 1.8371–3.1604), and this positive association was consistent in both men and women and among different race groups (Mexican American, other Hispanic, non-Hispanic White, Black, Asian, and other race). On the other hand, MUAC was positively associated with liver fibrosis in every multivariate linear regression model, and this positive association was consistent in both men and women and among non-Hispanic White and Black populations. Increased MUAC was positively associated with liver steatosis and fibrosis in patients with MAFLD. This was particularly true for MUAC ≥ 42.0 cm. MUAC might be a simple and convenient evaluation tool for MAFLD.
INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world, accounting for about 25% of the general population. The epidemiology and pathophysiology of NAFLD are closely connected to a variety of metabolic disorders, including obesity, type 2 diabetes mellitus (T2DM), and cardiovascular disease. The coexistence of NAFLD and these metabolic factors exacerbates the mortality of NAFLD-related liver diseases. In 2020, a new concept, metabolic-associated fatty liver disease (MAFLD), was proposed by international experts and was based on a set of positive diagnostic criteria for fatty liver disease associated with metabolic dysfunction. Steatosis, as the core factor in the diagnosis of MAFLD, and fibrosis, as the major determinant of adverse outcomes of MAFLD, need to be accurately assessed by physicians and researchers using concise methods.

In the past, the diagnosis of liver steatosis and fibrosis mainly depended on imaging-based methods, such as liver vibration-controlled transient elastography (VCTE) and magnetic resonance elastography. Although these methods are more accurate, specialist doctors are needed for their operation, and patients need to bear the costs for these examinations; these limitations are not helpful for the continuous monitoring and management of patients. This has led researchers to explore more accurate and practical tools for liver assessment. Anthropometric parameters, including the mid-upper arm circumference (MUAC), can be freely and easily obtained in the outpatient clinic. MUAC is a representative and noninvasive indicator for subcutaneous fat in the upper body, which is often suggested as a novel predictor of nutritional status, central obesity, and insulin resistance (IR). However, there are no published data to evaluate the association between MUAC and liver steatosis and fibrosis. In this study, we included 1640 participants with MAFLD and 757 participants with MAFLD combined with other chronic liver diseases from a national survey database. We explored the association between MUAC and liver steatosis and fibrosis detected by VCTE and evaluated the critical value of MUAC as a screening instrument for MAFLD.

MATERIALS AND METHODS

Study population

The 2017–2018 data set was obtained from the National Health and Nutrition Examination Surveys (NHANES) database (https://www.cdc.gov/nchs/nhanes/index.htm) and can be downloaded online for free. NHANES is a cross-sectional survey conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) in the United States and consists of demographic, dietary, examination, laboratory, and questionnaire data. The NHANES database is widely used in the study of liver diseases. The survey was approved by the CDC ethics review board, and all participants signed informed consent. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

VCTE

In the NHANES database, only participants in 2017–2018 underwent liver VCTE measurement using the FibroScan 502 V2 Touch (Echosens), which is suitable for the study of MAFLD. Controlled attenuation parameter (CAP) and liver stiffness measurements (LSMs) are validated parameters to measure liver steatosis and fibrosis in patients with fatty liver disease. Liver steatosis was evaluated by the mean of CAP in more than 10 complete operations, and fibrosis was estimated by the mean of LSM in more than 10 complete operations. Individuals without 10 complete FibroScan readings or having an interquartile range (IQR)/median liver stiffness >30% or a fasting time <3 hours were defined as having ineligible FibroScan measurements and were excluded from this study. Significant steatosis was defined as CAP ≥248 dB/m, and fibrosis was diagnosed as LSM ≥6.3 kPa.

Definition of MAFLD

Diagnostic criteria for MAFLD was based on evidence of liver steatosis (data from VCTE measurements in this study) and overweight/obesity (body mass index [BMI] ≥25 kg/m²) or T2DM (according to international criteria). If patients showed lean or normal weight and did not have T2DM, MAFLD was defined as the presence of liver steatosis and at least two of the following risk factors: (1) waist circumference ≥102 cm in men and 88 cm in women, (2) hypertension (≥130/85 mm Hg or under specific drug therapy), (3) hyperlipidemia (triglyceride [TG] ≥1.70 mmol/L or with specific drug treatment), (4) low high-density lipoprotein cholesterol (HDL-C) level (<1.0 mmol/L in men and <1.3 mmol/L in women), (5) prediabetes, and (6) hypersensitive C-reactive protein level >2 mg/L. Obese-MAFLD was defined as patients with MAFLD with BMI ≥25 kg/m²; nonobese-MAFLD was defined as patients with MAFLD with BMI <25 kg/m².

Variables

All variables were obtained from the NHANES data set. MUAC, as the independent variable, was measured...
MID-UPPER ARM CIRCUMFERENCE IS ASSOCIATED WITH LIVER STEATOSIS AND FIBROSIS IN PATIENTS WITH MAFLD

during the mobile examination center visit, and CAP and LSM, as dependent variables, were determined by VCTE measurement. For covariables, continuous variables included age, anthropometric measures (waist circumference), hip circumference, BMI (waist to hip ratio), fasting plasma glucose (FPG), total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase, albumin (ALB), alkaline phosphatase, uric acid (UA), hemoglobin A1c (HbA1c), sleep time; categorical variables included sex, race ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, other race), metabolic diseases (hypertension, diabetes, prediabetes, gout, coronary heart disease [CHD], stroke, thyroid problem), weight loss, medicine (antihypertension medicine, female hormones, and low-dose aspirin), and ratio of family income to poverty.

Statistical analysis

All statistical analyses were conducted using R 4.0.2 (http://www.R-project.org) and EmpowerStats (https://www.empowerstats.net/en/). p < 0.05 was considered statistically significant. Sample weights were used to calculate all estimates according to the analytical guideline provided by NCHS. We expressed continuous variables as mean ± SD. Categorical variables were expressed as n (percentages). We constructed three multivariable linear regression models. After stratification by age, sex, and race, analyses based on these three models were further performed in subgroups. To address nonlinearity associations, we also performed a weighted generalized additive model and a smooth curve fitting.

RESULTS

Baseline characteristics of participants with MAFLD

There were 9254 individuals in the 2017–2018 NHANES database. After excluding 3398 cases aged <18 years old, 1111 participants without eligible FibroScan data, 2006 cases with CAP < 248 dB/m, and 343 cases with no available MUAC and biochemistry data, a total of 2397 individuals were applicable for final analysis. All participants were divided into two groups according to whether they had MAFLD (1640 individuals) or MAFLD plus other chronic liver diseases (757 individuals), including heavy alcohol use, chronic hepatitis B, or chronic hepatitis C (Figure 1). The baseline characteristics of participants with MAFLD (n = 1640) are shown in Table 1. Based on a range of BMI values (25–29.9, 30–34.9, 35–39.9, ≥40 kg/m²),[16] patients with obese-MAFLD were further divided into four groups. Compared with participants with MAFLD but without obesity, participants with obese-MAFLD had significantly higher MUAC, waist circumference, hip
| Variables                      | Nonobese-MAFLD \( (n = 125) \) | Obese-MAFLD \( (n = 1515) \) | \( p \) value |
|-------------------------------|---------------------------------|------------------------------|--------------|
| **BMI (<25 kg/m²)**           |                                 |                              |              |
| Age (years)                   | 62.5 ± 12.8                     | 57.1 ± 16.4                  | <0.001       |
| Sex, n (%)                    |                                 |                              |              |
| Male                          | 72 (57.6)                       | 359 (61.5)                   | <0.001       |
| Female                        | 53 (42.4)                       | 225 (38.5)                   |              |
| Race, n (%)                   |                                 |                              | <0.001       |
| Mexican American              | 7 (5.6)                         | 95 (16.3)                    |              |
| Other Hispanic                | 9 (7.2)                         | 73 (12.5)                    |              |
| Non-Hispanic White            | 38 (30.4)                       | 179 (30.7)                   |              |
| Non-Hispanic Black            | 9 (7.2)                         | 81 (13.9)                    |              |
| Non-Hispanic Asian            | 57 (45.6)                       | 131 (22.4)                   |              |
| Mexican American              | 5 (4.0)                         | 25 (4.3)                     |              |
| **Anthropometric parameters** |                                 |                              |              |
| BMI (kg/m²)                   | 23.5 ± 1.2                      | 27.6 ± 1.4                   | <0.001       |
| MUAC (cm)                     | 28.8 ± 1.9                      | 32.1 ± 2.4                   | <0.001       |
| Waist circumference (cm)      | 89.5 ± 6.0                      | 98.2 ± 7.1                   | <0.001       |
| Hip circumference (cm)        | 94.2 ± 4.2                      | 101.9 ± 5.3                  | <0.001       |
| Waist to hip ratio            | 1.0 ± 0.1                       | 1.0 ± 0.1                    | <0.001       |
| **VCTE parameters**           |                                 |                              |              |
| CAP (dB/m)                    | 290.1 ± 33.4                    | 297.1 ± 33.8                 | <0.001       |
| Stiffness (kPa)               | 5.3 ± 3.8                       | 5.7 ± 4.7                    | <0.001       |
| **Serum test**                |                                 |                              |              |
| FPG (mmol/L)                  | 6.6 ± 3.0                       | 6.0 ± 2.1                    | 0.037        |
| TC (mmol/L)                   | 5.2 ± 1.2                       | 5.0 ± 1.1                    | 0.001        |
| TG (mmol/L)                   | 2.2 ± 1.3                       | 1.9 ± 1.4                    | 0.233        |
| HDL-C (mmol/L)                | 1.3 ± 0.4                       | 1.3 ± 0.3                    | 0.002        |
| TBLI (μmol/L)                 | 8.5 ± 5.6                       | 8.4 ± 4.8                    | <0.001       |
| ALB (g/L)                     | 41.5 ± 3.2                      | 41.3 ± 3.0                   | <0.001       |
| ALT (U/L)                     | 22.4 ± 12.9                     | 22.9 ± 13.9                  | 0.010        |
| AST (U/L)                     | 22.2 ± 8.3                      | 21.5 ± 9.9                   | 0.157        |
| GGT (U/L)                     | 36.9 ± 63.4                     | 31.8 ± 30.3                  | 0.525        |
| ALP (U/L)                     | 82.5 ± 29.5                     | 80.5 ± 22.7                  | 0.007        |
| Creatinine (μmol/L)           | 83.3 ± 56.8                     | 82.0 ± 33.4                  | 0.298        |
| UA (μmol/L)                   | 330.0 ± 84.2                    | 338.7 ± 83.6                 | <0.001       |
| HbA1c (%)                     | 6.4 ± 1.6                       | 6.1 ± 1.3                    | 0.013        |
| **Metabolic diseases**        |                                 |                              |              |
| Hypertension, n (%)           | 45 (36.0)                       | 147 (25.2)                   | 0.034        |

(Continues)
Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with MAFLD.

Circumference, waist to hip ratio, liver CAP and stiffness values, UA and HbA1c levels, and percentages of patients with diabetes, prediabetes, CHD, stroke, and trouble sleeping; however, these participants had lower age, HDL-C, TBIL, ALB, and AST levels. In particular, age, anthropometric parameters, and VCTE parameters increased significantly with the increase in BMI (Table 1). We also analyzed the baseline characteristics of patients with MAFLD with other liver diseases. Except anthropometric and VCTE parameters, individuals with obesity showed higher ALT levels but lower percentages of cases with hypertension, diabetes, gout, and CHD than participants without obesity (Table S1).

### Multivariate analysis for MUAC and liver steatosis

Based on the increase of BMI in all our participants, MUAC and liver CAP values showed a similar increasing trend (Figure S1). Multivariate linear regression analysis was further performed to evaluate the association between MUAC and liver steatosis. Three models were used to evaluate \( \beta \) (95% CI) of the MUAC. In model 1, no covariates were adjusted. For model 2, age, sex, and race were adjusted. Model 3 was adjusted for additional hypertension; waist to hip ratio; the level of FPG, HDL, ALT, TG, and UA; obesity; and median liver stiffness on the basis of model 2.

### Table 1 (Continued)

| Variables                      | Nonobese-MAFLD (n = 125) | Obese-MAFLD (n = 1515) |
|--------------------------------|---------------------------|-------------------------|
|                                | BMI (<25 kg/m²)           | BMI (25–29.9 kg/m²) n = 584 | BMI (30–34.9 kg/m²) n = 471 | BMI (35–39.9 kg/m²) n = 263 | BMI (≥40 kg/m²) n = 197 | p value |
| Diabetes, n (%)                | 42 (33.6)                 | 123 (21.1)              | 113 (24.0)              | 59 (22.4)              | 63 (32.0)              | 0.004   |
| Prediabetes, n (%)             | 10 (8.0)                  | 65 (11.1)               | 55 (11.7)               | 39 (14.8)               | 30 (15.2)               | <0.001  |
| Gout, n (%)                    | 19 (15.2)                 | 41 (7.0)                | 24 (5.1)                | 20 (7.6)                | 18 (9.1)                | 0.004   |
| CHD, n (%)                     | 13 (10.4)                 | 32 (5.5)                | 33 (7.0)                | 14 (5.3)                | 12 (6.1)                | 0.170   |
| Stroke, n (%)                  | 6 (4.8)                   | 20 (3.4)                | 22 (4.7)                | 20 (7.6)                | 9 (4.6)                 | 0.076   |
| Thyroid problem, n (%)         | 13 (10.4)                 | 66 (11.3)               | 79 (16.8)               | 39 (14.8)               | 23 (11.7)               | 0.047   |

**Sleep time (hours)**

|                  | Weekdays | Weekends | Trouble with sleep, n (%) |
|------------------|----------|----------|---------------------------|
|                  | 7.8 ± 1.7 | 8.3 ± 1.6 | 28 (22.4)                 |
|                  | 7.5 ± 1.6 | 8.2 ± 1.7 | 129 (22.1)                |
|                  | 7.5 ± 1.6 | 8.2 ± 1.7 | 149 (31.6)                |
|                  | 7.5 ± 1.6 | 8.1 ± 1.7 | 98 (37.3)                 |
|                  | 7.4 ± 1.8 | 8.1 ± 1.9 | 87 (44.2)                 |
|                  | 0.162     | 0.576     | <0.001                    |

**Weight loss, n (%)**

|                  | Weekdays | Weekends | Trouble with sleep, n (%) |
|------------------|----------|----------|---------------------------|
|                  | 84 (67.2) | 406 (69.5) | 191 (72.6)                |
|                  | 406 (69.2) | 326 (69.2) | 133 (67.5)                |
|                  | 326 (69.2) | 191 (72.6) | 133 (67.5)                |
|                  | 0.753     |          |                           |

**Medicine, n (%)**

|                | Hypertension | Female hormones | Low-dose aspirin |
|----------------|--------------|-----------------|------------------|
|                | 45 (36.0)    | 14 (11.2)       | 39 (31.2)        |
|                | 213 (36.5)   | 47 (7.0)        | 177 (30.3)       |
|                | 201 (42.7)   | 41 (8.7)        | 158 (33.5)       |
|                | 118 (44.9)   | 27 (10.3)       | 80 (30.4)        |
|                | 87 (44.2)    | 20 (10.2)       | 73 (37.1)        |
|                | <0.001       | <0.001          | 0.610            |

**Ratio of family income to poverty**

|                | <1.0         | 1.0 to <2.0     | 2.0 to <3.0      |
|----------------|--------------|-----------------|-----------------|
|                | 16 (12.8)    | 26 (20.8)       | 27 (21.6)       |
|                | 69 (11.8)    | 148 (25.3)      | 82 (14.0)       |
|                | 61 (13.0)    | 98 (20.8)       | 79 (16.8)       |
|                | 52 (19.8)    | 67 (25.5)       | 36 (13.7)       |
|                | 40 (10.3)    | 55 (27.9)       | 36 (18.3)       |
|                | <1.0         | 1.0 to <2.0     | 2.0 to <3.0      |
|                | 18 (14.4)    | 111 (19.0)      | 86 (18.3)       |
|                | 19 (15.2)    | 92 (15.8)       | 79 (16.8)       |
|                | 19 (15.2)    | 92 (15.8)       | 79 (16.8)       |

**Note:** Continuous variables are shown as mean ± SD. Categorical values are shown as n (%).

**Abbreviations:** ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CHD, coronary heart disease; FPG, fasting plasma glucose; GGT, γ-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; MAFLD, metabolic-associated fatty liver disease; MUAC, mid-upper arm circumference; NA, not available; NHANES, National Health and Nutrition Examination Survey; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride; UA, uric acid; VCTE, vibration controlled transient elastography.
The results of the multivariable analysis showed that MUAC was positively associated with the liver CAP value of patients with MAFLD in each multivariable linear regression model (Table 2). This trend remained significant among different MUAC quartile groups ($p<0.001$). The positive association was also observed in both men ($\beta = 3.7379; 95\% \text{ CI}, 2.6379–4.8018; p<0.001$) and women ($\beta = 1.6706; 95\% \text{ CI}, 0.8381–2.5031; p<0.001$) as well as in all racial subgroups (Table 2). We used a weighted generalized additive model and a smooth curve fitting to address the nonlinear relationship and confirmed that liver CAP values increased consistently with the increase of MUAC (Figure 2A–E). Although there were subtle differences, the relationship between MUAC and liver CAP values in patients with MAFLD with other chronic liver diseases was similar to patients with MAFLD (Table S2; Figure S2A–E).

### Multivariate analysis for MUAC and liver fibrosis

Similarly, we also observed a simultaneous and increasing trend in MUAC and liver stiffness value with the increase in BMI in all our cases (Figure S1).

| TABLE 2 | Multivariate analysis for the relationship between MUAC and liver steatosis in patients with MAFLD (CAP) |
| --- | --- |
| **Model 1, $\beta$ (95\% CI) $p$ value** | **Model 2, $\beta$ (95\% CI) $p$ value** | **Model 3, $\beta$ (95\% CI) $p$ value** |
| Baseline MUAC | 2.7620 (2.3661, 3.1580) $<0.000001$ | 3.1050 (2.6884, 3.5216) $<0.000001$ | 2.1389 (1.7021, 2.5757) $<0.000001$ |
| Quartiles of MUAC | | | |
| **Q1 (22.5–32.0 cm)** | Reference | Reference | Reference |
| **Q2 (32.1–34.8 cm)** | 9.1144 (3.4647, 14.7608) $0.001586$ | 10.7911 (5.1185, 16.4637) $0.000199$ | 6.9184 (1.1925, 12.6442) $0.017991$ |
| **Q3 (34.9–38.2 cm)** | 20.1829 (14.8649, 25.5009) $<0.000001$ | 22.4020 (16.9414, 27.8627) $<0.000001$ | 14.4033 (8.7783, 20.0282) $<0.000001$ |
| **Q4 (38.3–56.3 cm)** | 33.2188 (27.8287, 38.6089) $<0.000001$ | 37.1152 (31.4632, 42.7672) $<0.000001$ | 22.4071 (18.6802, 30.5340) $<0.000001$ |
| $p$ for trend | $<0.001$ | $<0.001$ | $<0.001$ |
| Stratified by sex | | | |
| Men | 3.3304 (2.7329, 3.9280) $<0.000001$ | 3.8604 (3.2356, 4.4852) $<0.000001$ | 2.3599 (1.6772, 3.0426) $<0.000001$ |
| Women | 2.0622 (1.5481, 2.5763) $<0.000001$ | 2.3727 (1.8319, 2.9135) $<0.000001$ | 1.8694 (1.3030, 2.4357) $<0.000001$ |
| Stratified by race | | | |
| Mexican American | 2.3470 (1.1959, 3.4981) $<0.000008$ | 2.3356 (1.1729, 3.4983) $<0.000108$ | 1.5825 (0.4047, 2.7603) $0.09015$ |
| Other Hispanic | 3.3735 (1.7805, 4.9665) $<0.000055$ | 3.8057 (2.1246, 5.4869) $<0.000018$ | 3.2833 (1.4848, 5.0818) $0.000476$ |
| Non-Hispanic White | 2.8995 (2.2309, 3.5681) $<0.000001$ | 3.1294 (2.4313, 3.8214) $<0.000001$ | 1.9706 (1.2625, 2.6788) $<0.000001$ |
| Non-Hispanic Black | 2.3687 (1.4438, 2.2935) $<0.000001$ | 2.7771 (1.8441, 3.7101) $<0.000001$ | 2.5752 (1.5570, 3.5933) $<0.000001$ |
| Non-Hispanic Asian | 2.5474 (1.4685, 3.6263) $<0.000006$ | 3.0230 (1.8277, 4.2184) $<0.000001$ | 1.9308 (0.6167, 3.2448) $0.004328$ |
| Other race | 3.4356 (2.0366, 4.8346) $<0.000007$ | 4.2583 (2.6799, 5.8367) $<0.000001$ | 3.1664 (0.8966, 5.4363) $0.07992$ |

**Note:** Model 1: No covariates were adjusted. Model 2: Sex, age, and race were adjusted. Model 3: Sex, age, race, waist to hip ratio, fasting plasma glucose, high-density lipoprotein cholesterol, alanine aminotransferase, triglyceride, uric acid, hypertension, obesity, and median liver stiffness were adjusted. Abbreviations: CAP, controlled attenuation parameter; CI, confidence interval; MAFLD, metabolic-associated fatty liver disease; MUAC, mid-upper arm circumference; Q, quartile.

*a* In the subgroup analysis stratified by sex or race, models 1–3 were not adjusted for their own stratification variable.
MID-UPPER ARM CIRCUMFERENCE IS ASSOCIATED WITH LIVER STEATOSIS AND FIBROSIS IN PATIENTS WITH MAFLD

In this multivariable analysis, model 1 and model 2 were adjusted for the same variables as in liver steatosis. Except for other variables in liver steatosis, model 3 was also adjusted for the median liver CAP value instead of median liver stiffness (Table 3). The positive relationship between MUAC and liver stiffness existed in each model ($p<0.001$). The positive association was also observed in both men ($\beta = 0.3347; 95\% \text{ CI}, 0.1626–0.5068; p<0.001$) and women ($\beta = 0.5007; 95\% \text{ CI}, 0.3171–0.6842; p<0.001$). However, after being stratified by quartiles of MUAC, the positive association only persisted in the fourth quartile (38.3–56.3 cm) in models 1–3. With an increase of MUAC, the positive correlation became more obvious. Moreover, in the subgroup analysis stratified by race, the positive relation between MUAC and liver fibrosis was only present in the non-Hispanic White and Black populations ($p<0.01$) (Table 3). A weighted generalized additive model and a smooth curve fitting was also used to illustrate the nonlinear relationship (Figure 3A–E). We found that at MUAC≥42.0 cm (95\% CI, 39.3–42.5), MUAC provided a better evaluation parameter for liver fibrosis (Figure 3A,B). In addition, MUAC≥42.0 cm (95\% CI, 39.6–42.9) provided a better evaluation parameter for liver fibrosis in men (red line), and MUAC≥42.6 cm (95\% CI, 38.9–45.3) provided a better evaluation parameter for liver fibrosis in women (blue line) (Figure 3D). However, in patients with MAFLD plus other liver diseases, the positive relationship between MUAC and liver stiffness was not apparent in women or different racial subgroups (Table S3; Figure S3).

**DISCUSSION**

This study is the first population-based study to explore the association between MUAC and liver steatosis and fibrosis detected by VCTE in adults with MAFLD from the NHANES database. Our results suggest that increased MUAC is associated with increased liver steatosis and fibrosis, especially with liver steatosis. Although some nonlinear relations were observed, these trends still existed in multivariable linear regressions. This finding indicates that MUAC could be used as an easily available and simple evaluation instrument for liver steatosis and fibrosis.

The diagnosis of NAFLD was often accompanied by overweight, obesity, and glucose and lipid metabolism...
disorders, and the pathogenesis of NAFLD and other metabolic disorders was closely interconnected. Many experts in the field of NAFLD are now calling for a change in its terminology. Therefore, MAFLD, as a new definition, has been suggested to physicians. In our study, compared with patients with nonobese-MAFLD, patients with obese-MAFLD had higher anthropometric parameters, liver CAP, and stiffness values; higher levels of biochemical indicators related to metabolism and inflammation; and younger ages. These results are similar to findings in a study from the Philippines that found that patients with obese-NAFLD were more likely to be younger; had T2DM, hypertension, dyslipidemia, and metabolic syndrome (MS); and had abnormal metabolic parameters (elevated ALT and AST levels, low-density lipoprotein cholesterol, HDL-C, TG, and UA) than patients with lean-NAFLD. It was easy for us to understand that nonobese-NAFLD was considered to have a more favorable biochemical profile and less severe liver histologic injury. However, another study found no differences in the percentages of diabetes mellitus, MS, abnormal obesity, hypertension, and dyslipidemia between nonobese- and obese-NAFLD. In addition, patients without obesity were usually older, which was associated with liver cirrhosis and led to further decreases in weight. In our study, we also found

| TABLE 3 | Multivariate analysis for the relationship between MUAC and liver fibrosis in patients with MAFLD (LSM) |
|---------|----------------------------------------------------------------------------------------------------|
|         | Model 1, β (95% CI) | Model 2, β (95% CI) | Model 3, β (95% CI) |
|         | p value (n = 1640) | p value (n = 1640) | p value (n = 1640) |
| Baseline MUAC | 0.2355 (0.1899, 0.2810) | 0.2703 (0.2223, 0.3183) | 0.2088 (0.1554, 0.2622) |
| <0.000001 | <0.000001 | <0.000001 |
| Quartiles of MUAC | | | |
| Q1 (22.5–32.0 cm) | Reference | Reference | Reference |
| Q2 (32.1–34.8 cm) | 0.3572 (0.2998, 1.0133) | 0.4105 (0.2508, 1.0717) | 0.223905 |
| 0.286040 | 0.223905 |
| Q3 (34.9–38.2 cm) | 0.5626 (0.0553, 1.1805) | 0.7253 (0.0888, 1.3618) | 0.223905 |
| 0.1074512 | 0.223905 |
| Q4 (38.3–56.3 cm) | 2.0124 (1.3862, 3.6387) | 2.2681 (1.6093, 2.9269) | 1.1328 (0.3968, 1.8688) |
| <0.000001 | <0.000001 | 0.002597 |
| <0.001 | <0.001 | 0.003 |
| p for trend | | | |
| Stratified by sex** | | | |
| Men | 0.3246 (0.2494, 0.3998) | 0.3625 (0.2839, 0.4411) | 0.2749 (0.1824, 0.3674) |
| <0.000001 | <0.000001 | <0.000001 |
| Women | 0.1405 (0.0918, 0.1892) | 0.1716 (0.1205, 0.2227) | 0.1378 (0.0850, 0.1907) |
| <0.000001 | <0.000001 | <0.000001 |
| Stratified by race** | | | |
| Mexican American | 0.1317 (0.0134, 0.2500) | 0.1520 (0.0337, 0.2702) | 0.1125 (0.0129, 0.2379) |
| 0.030053 | 0.079594 |
| Other Hispanic | 0.1866 (0.1161, 0.4893) | 0.2341 (0.0814, 0.5495) | 0.357921 |
| 0.1228925 | 0.375921 |
| Non-Hispanic White | 0.2200 (0.1490, 0.2911) | 0.2413 (0.1671, 0.3155) | 0.1802 (0.0979, 0.2625) |
| <0.000001 | <0.000001 | <0.000001 |
| Non-Hispanic Black | 0.2434 (0.1559, 0.3309) | 0.2562 (0.1662, 0.3463) | 0.2179 (0.1180, 0.3179) |
| <0.000001 | <0.000001 | <0.000001 |
| Non-Hispanic Asian | 0.1275 (0.0471, 0.2079) | 0.1976 (0.1086, 0.2848) | 0.1425 (0.0440, 0.2410) |
| 0.002086 | 0.004942 |
| Other race | 0.6681 (0.4615, 0.9147) | 0.8091 (0.5606, 1.0576) | 0.5876 (0.2359, 0.9393) |
| <0.000001 | <0.000001 | 0.001678 |

Note: Model 1: No covariates were adjusted. Model 2: Sex, age, and race were adjusted. Model 3: Sex, age, race, waist to hip ratio, glucose, high-density lipoprotein cholesterol, alanine aminotransferase, triglyceride, hypertension, obesity, median controlled attenuation parameter, and uric acid were adjusted.

Abbreviations: CI, confidence interval; LSM, liver stiffness measurement; MAFLD, metabolic-associated fatty liver disease; MUAC, mid-upper arm circumference; Q, quartile.

**In the subgroup analysis stratified by sex or race, models 1–3 were not adjusted for their own stratification variable.
that patients with nonobese-MAFLD were older and had a higher BMI; however, lower liver stiffness values, which might be due to patients without obesity but with fatty liver, have fewer metabolic factors associated with the progression of fibrosis, such as IR or the balance and interaction among bile acids, the intestinal microbiome, and systemic metabolism.[21,24]

In our study, we observed that MUAC was positively associated with liver steatosis in both sex groups and among different race groups. Generally, BMI or waist to hip ratio is commonly used in evaluating obesity and NAFLD. However, there are limitations in the evaluation of these two parameters, such as cirrhotic ascites and lean-NAFLD, BMI includes body weight and height (which is somewhat complicated to calculate), and BMI value is weakly associated with visceral and liver fat.[25,26] MUAC is a representative index for subcutaneous fat in the upper body and is a reliable screening measure for identifying abnormal regional fat distribution, which is less affected by fluid retention.[27,28]

Although no previous studies have directly proposed a relationship between MUAC and liver steatosis in patients with MAFLD, some researchers have illustrated that a larger MUAC is significantly associated with central obesity and MS.[9,29–32] In addition, MUAC has been commonly used as a simple tool for estimating nutritional status and sarcopenia; patients with sarcopenia had a significantly lower MUAC compared with those without sarcopenia.[11,32,33] Therefore, MUAC is closely associated with the metabolic profile of the human body and might be a relatively simple indicator for assessment of liver steatosis in patients with MAFLD.

Clinical factors known to be independently predictive of fibrosis in nonalcoholic steatohepatitis include age, obesity, and T2DM.[34] In line with this, we found that liver stiffness in patients with MAFLD increased with an increase in BMI. This is a new topic for exploring the association between MUAC and liver fibrosis in patients with MAFLD. In our study, we further found that MUAC (especially MUAC ≥42.0 cm) was positively associated with liver stiffness in patients with MAFLD in both men and women and among non-Hispanic individuals. At present, there is no published evidence to document a direct relation between MUAC and liver fibrosis in patients with MAFLD. An earlier study investigated whether peripheral and/or abdominal adipose depot size correlated
with stage of liver fibrosis in patients with NAFLD and found that men with smaller extremity sizes (z scores of MUAC and hip circumference) and premenopausal women with larger extremity sizes were more likely to have more severe fibrosis. However, another study found that the arm fat index, a parameter that reflects upper body fat, was negatively associated with liver fibrosis in patients with NAFLD. Therefore, controversies in the relationship between MUAC and liver fibrosis in MAFLD still exist, and the representative significance of MUAC for liver fibrosis needs to be assessed in a larger MAFLD population.

In conclusion, MUAC was independently associated with liver steatosis and fibrosis (especially MUAC ≥ 42.0 cm) in patients with MAFLD and might be a simple and convenient tool in the evaluation of MAFLD. In the future, we need to measure MUAC routinely in the outpatient clinic; this will be helpful in the preliminary assessment of the degree of liver steatosis and fibrosis and in the rapid diagnosis and treatment of patients with MAFLD.

CONFLICTS OF INTEREST
Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20.
2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158:1851–64.
3. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimising liver outcomes. Diabetes Obes Metab. 2022;24(Suppl 2):44–54.
4. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Lai Wei has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and served as a consultant for Gilead, Huahui, MSD, Pfizer, a speaker for Ascletis Pharma, Bristol-Myers Squibb, Gilead and Kaiyin. The other authors have nothing to report.
MID-UPPER ARM CIRCUMFERENCE IS ASSOCIATED WITH LIVER STEATOSIS AND FIBROSIS IN PATIENTS WITH MAFLD

28. Akin S, Mucuk S, Ozturk A, Mazicioglu M, Gocer S, Arguvanli S, et al. Muscle function-dependent sarcopenia and cut-off values of possible predictors in community-dwelling Turkish elderly: calf circumference, midarm muscle circumference and walking speed. Eur J Clin Nutr. 2015;69:1087–90.

29. Nitika N. Discriminatory ability of mid-upper arm circumference in identifying overweight and obese adolescents: findings from the comprehensive national nutrition survey, India. Indian J Public Health. 2021;65:269–74.

30. Asif M, Aslam M, Ullah K, Qasim M, Afzal K, Abbas A, et al. Diagnostic performance and appropriate cut-offs of different anthropometric indicators for detecting children with overweight and obesity. Biomed Res Int. 2021;2021:1608760.

31. Shi J, Yang Z, Niu Y, Zhang W, Li X, Zhang H, et al. Large mid-upper arm circumference is associated with metabolic syndrome in middle-aged and elderly individuals: a community-based study. BMC Endocr Disord. 2020;20:78.

32. Das A, Saimala G, Reddy N, Mishra P, Giri R, Kumar A, et al. Mid-upper arm circumference as a substitute of the body mass index for assessment of nutritional status among adult and adolescent females: learning from an impoverished Indian state. Public Health. 2020;179:68–75.

33. Endo K, Sato T, Kakisaka K, Takikawa Y. Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease. Hepatol Res. 2021;51:176–89.

34. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.

35. Suzuki A, Abdelmalek MF, Unalp-Arida A, Yates K, Sanyal A, Guy C, et al. Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2010;8:1062–9.

36. Subramanian V, Johnston RD, Kaye P, Aithal GP. Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37:455–63.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Wang X, Li X, Jin R, Yang J, Huang R, Wei L, et al. Mid-upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease: A population based observational study. Hepatol Commun. 2022;6:2262–2272. https://doi.org/10.1002/hep4.1990